Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Image captured and color-enhanced at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland.
Credit: National Institute of Allergy and Infectious Diseases, NIH
A group of scientists, physicians, funders, and policy makers from over 70 institutions from over 30 countries have launched an international coalition to respond to COVID-19 in resource-poor settings.
The COVID-19 Clinical Research Coalition aims to accelerate desperately needed COVID-19 research in those areas where the virus could wreak havoc on already-fragile health systems and cause the greatest health impact on vulnerable populations.
In a Comment published today in The Lancet, the members of the coalition argue that international research collaboration and coordination is needed urgently to support African, Latin American, Eastern European, and certain Asian countries to respond effectively to the worsening pandemic and speed up research adapted to resource-limited settings.
The coalition brings together an unprecedented array of health experts, including public-sector research institutes, ministries of health, academia, not-for-profit research and development organizations, NGOs, international organisations, and funders all committed to finding COVID-19 solutions for resource-poor settings.
One important research response to COVID-19 has been launched already, the World Health Organization (WHO)-led SOLIDARITY trial, an unprecedented global effort. But the authors found that out of almost 600 COVID-19 clinical trials registered, very few trials are planned in resource-poor settings. The authors commit to sharing their technical expertise and clinical trial capability to accelerate COVID-19 research in these settings.
The scale of the challenge is clearly beyond the scope of any single organization. The coalition will facilitate a coordinated approach, so that all data from all regions can be collected in a similar fashion, pooled and shared in real-time. This will help countries and the WHO to make rapid evidence-based decisions on policies and practice.
“We welcome the launch of this coalition, which takes advantage of existing multinational and multidisciplinary expertise in running clinical trials in resource poor settings, and will help the World Health Organization in its coordinating role in the global response to COVID-19,” said Dr Soumya Swaminathan, Chief Scientist, World Health Organization. “Although the epicentre is today elsewhere, we must prepare now for the consequences of this pandemic in more resource-constrained settings or we stand to lose many more lives.”
Members of the coalition call for specific commitments to ensure access, so that effective new treatments are made available as soon as possible in resource-poor settings and are affordable and readily accessible.
So far more than 70 organizations have joined this coalition, with a call made to other organizations ready to contribute existing capacity to join. Please contact the COVID-19 Clinical Research Coalition for more information: [email protected]
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
COVID-19 in resource-poor settings
- Scientists race to find 'warm' Covid vaccine to solve issue of cold storageon November 20, 2020 at 12:25 am
With potential injectable vaccines estimated to be out of reach for two-thirds of world’s population, scientists hope to find less-heat-sensitive formulations ...
- With the floods come deadly leptospirosison November 16, 2020 at 3:59 pm
With the heavy rains and floods, COVID-19 will temporarily take a back seat ... Laboratory confirmation can be a challenge in resource-poor settings, especially during outbreaks.
- Freezers Needed: Pfizer’s Coronavirus Vaccine Needs to Be Kept Cold While It Is Distributedon November 16, 2020 at 12:09 am
One complicating factor will be the maintenance of the cold chain. Vaccines are fragile products: they need to be stored at specific temperatures, and some are sensitive to light and need to be ...
- What The Experts Are Saying About The COVID-19 Vaccine From Pfizeron November 12, 2020 at 11:59 pm
Health care experts and scientists have weighed in, and their conclusion is that this is good news for a number of reasons—with a few doses of reality.
- Pfizer's ultra-cold vaccine could be difficult to distributeon November 10, 2020 at 11:33 pm
The excitement that greeted the news of a vaccine candidate that may be highly effective against COVID-19 was indeed something to behold. If the final results show anything like the numbers quoted in ...
Go deeper with Google Headlines on:
COVID-19 in resource-poor settings
Go deeper with Bing News on:
Prevention and treatment of COVID-19
- COVID-19 hospitalizations continue surge to record level, with EMMC and MaineGeneral bearing biggest burdenson November 21, 2020 at 11:11 am
In contrast to the spring, Portland’s hospitals haven’t seen the number of COVID-19 inpatients grow as sharply during the ongoing surge.
- Lilly’s neutralizing antibody bamlanivimab (LY-CoV555) receives interim authorization from Health Canada as a treatment for COVID-19on November 21, 2020 at 7:47 am
Health Canada today granted authorization under the Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19 for the use of bamlanivimab (LY-CoV555) as a ...
- Sanford Health executives disavow CEO's email about COVID-19 and maskson November 20, 2020 at 9:53 pm
"We know that words matter, and words have power, and we regret that the message left many frustrated and disappointed," wrote the executives, with President and CEO Kelby Krabbenhoft's signature ...
- AstraZeneca starts new COVID-19 prevention trials of antibody cocktailon November 20, 2020 at 9:07 pm
AstraZeneca started late-stage trials on Saturday of an experimental long-acting monoclonal antibody combination drug it hopes could be used as a so-called prophylactic to prevent COVID-19 ...
- AbCellera-Discovered Antibody Granted Interim Authorization by Health Canada as a Treatment for COVID-19on November 20, 2020 at 5:49 pm
AbCellera today announced that bamlanivimab (LY-CoV555) 700 mg, a human antibody developed through AbCellera’s collaboration with Eli Lilly and Company (Lilly), was granted authorization by Health ...